Mary Theresa Coelho - 09 Sep 2021 Form 4 Insider Report for AzurRx BioPharma, Inc. (ENTO)

Role
Director
Signature
/s/ Mary Theresa Coelho
Issuer symbol
ENTO
Transactions as of
09 Sep 2021
Net transactions value
$0
Form type
4
Filing time
13 Sep 2021, 20:08:11 UTC
Previous filing
17 Aug 2021
Next filing
03 Jan 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FWBI Stock option (right to buy) Award $0 +10,310 $0.000000 10,310 09 Sep 2021 Common stock, par value $0.0001 per share 10,310 $0.6400 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of derivative securities reported has not been adjusted to reflect the 10-for-1 reverse stock split of AzurRx BioPharma, Inc. common stock that occurred on September 13, 2021.
F2 The stock option vests on December 31, 2021.